1. Quick Facts
Category: Growth Hormone Releasing Hormone (GHRH) Analog
Risk Level: Moderate/High
Research Status: Emerging Research
Administration: Subcutaneous Injection
Typical Frequency: 1–3 Times Daily
Estimated Half-Life: Approximately 30 Minutes
Primary Research Interest: Pulsatile Growth Hormone Release / Recovery / IGF-1 Support
This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. CJC-1295 No DAC (Modified GRF 1-29) is a biologically active GHRH analog capable of significantly altering growth hormone, IGF-1, metabolic, and recovery signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
CJC-1295 No DAC (Modified GRF 1-29) is an experimental short-acting Growth Hormone Releasing Hormone (GHRH) analog researched for its potential effects on pulsatile growth hormone release, recovery support, IGF-1 signaling, and body composition pathways.
Unlike CJC-1295 DAC, which was engineered for prolonged endocrine stimulation, Modified GRF 1-29 was designed to improve the stability of native GHRH while preserving a short duration of action. This allows for transient growth hormone pulses that more closely resemble natural physiologic secretion patterns.
What People Commonly Claim
- More physiologic growth hormone release than CJC-1295 DAC
- Improved recovery, muscle gain, and fat loss
- Less water retention than DAC-based protocols
- Superior when paired with Ipamorelin
- More natural growth hormone pulsing
What the Literature Actually Shows
- Modified GRF 1-29 was engineered to improve the stability and activity of native Growth Hormone Releasing Hormone.
- The peptide stimulates endogenous growth hormone release through GHRH receptor activation.
- Its short duration produces transient growth hormone pulses rather than prolonged endocrine elevation.
- Human evidence supporting improved recovery, athletic performance, muscle gain, or fat loss remains limited.
- Many timing strategies, stacking protocols, and performance claims originate primarily from anecdotal reports rather than controlled clinical trials.
CKF Note: CJC-1295 No DAC is commonly referred to in the scientific literature as Modified GRF 1-29. While many peptide suppliers market the compound as “CJC-1295 No DAC,” most published studies use Modified GRF 1-29 terminology. Readers reviewing scientific literature should be aware that these names generally refer to the same compound.
CKF Note: CJC-1295 No DAC (Modified GRF 1-29) is frequently discussed alongside growth hormone secretagogues such as Ipamorelin. While this combination is common within peptide communities, high-quality human studies directly evaluating the combination remain limited.
3. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
CJC-1295 No DAC (Modified GRF 1-29) is most commonly administered as a short-acting subcutaneous injectable GHRH analog.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered during fasted periods
- Administration Notes: Frequently researched alongside GHRP compounds and pulsatile growth hormone protocols.
5. Common Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 100–300 mcg per dose
- Frequency: 1–3 times daily
- Cycle Length: 8–16 weeks on / 4–8 weeks off
- Special Notes: Unlike the DAC version, CJC-1295 No DAC is intentionally short-acting and is commonly used to create sharper pulsatile growth hormone release rather than prolonged elevation. Because of its shorter duration, researchers frequently administer it multiple times daily and often pair it with GHRPs such as Ipamorelin, GHRP-2, or Hexarelin to amplify pulse signaling. Many users prefer fasted administration timing to help minimize insulin and blood-glucose interference with growth hormone release. Compared to CJC-1295 DAC, the No DAC version is generally discussed as producing less sustained IGF-1 elevation and potentially less water retention, though it requires substantially more frequent administration.
6. Mechanism of Action
CJC-1295 No DAC (Modified GRF 1-29) functions by stimulating Growth Hormone Releasing Hormone receptors within the pituitary gland to promote endogenous growth hormone release.
- Pulsatile growth hormone release signaling
- IGF-1 pathway support
- Recovery signaling support
- Potential sleep-quality enhancement
- Metabolic pathway modulation
- Short-duration peptide activity
Unlike DAC-modified versions, the No DAC variant is specifically designed for shorter and more pulse-oriented receptor activation. Its amino acid substitutions improve resistance to enzymatic degradation while maintaining a relatively brief duration of action.
7. Potential Benefits
- Potential increase in pulsatile growth hormone signaling
- Enhanced recovery support
- Possible sleep-quality improvements
- Potential body composition support
- Possible connective tissue recovery support
- Potential synergistic effects with GHRP compounds
8. Potential Risks / Side Effects
Moderate/High
- Water retention
- Numbness or tingling
- Fatigue
- Potential insulin sensitivity changes
- Elevated IGF-1 signaling
- Possible joint discomfort
- Injection-frequency burden due to short duration
9. Half-Life
CJC-1295 No DAC (Modified GRF 1-29) is commonly reported to have a circulating half-life of approximately 30 minutes.
This short duration contrasts substantially with the prolonged activity profile of CJC-1295 DAC and is one reason why multiple daily administrations are frequently discussed.
Although circulating concentrations decline rapidly, downstream growth hormone and IGF-1 signaling effects may persist beyond the measurable plasma half-life.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Active cancer concerns
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside multiple hormone-modulating compounds without appropriate supervision
12. Further Study
Modified GRF 1-29 has a long developmental history within Growth Hormone Releasing Hormone research and is frequently discussed within peptide communities. However, many foundational publications remain accessible only through journal subscriptions or institutional access.
Recommended Reading
The Development of Growth Hormone-Releasing Hormone Agonists and Antagonists
A comprehensive review of GHRH analog development, physiology, and therapeutic research.
Synthesis of New Potent Agonistic Analogs of Growth Hormone-Releasing Hormone
Explores the structure-activity relationships and peptide engineering principles that led to modern GHRH analogs.
CKF Transparency Note: Modified GRF 1-29 is widely discussed within peptide communities and has a substantial developmental history within endocrinology research. However, many foundational publications remain accessible only through journal subscriptions or institutional access. In accordance with CKF standards, only freely accessible full-text resources are recommended here. Readers should be aware that the limited Further Study section reflects article accessibility rather than a lack of scientific interest in the compound.
Current Evidence Gaps
- Direct muscle-gain outcomes in healthy adults
- Direct recovery outcomes in healthy adults
- Fat-loss outcomes in healthy adults
- Long-term outcome data
- CJC-1295 No DAC plus Ipamorelin combination studies
- Direct comparative trials versus CJC-1295 DAC
CKF Summary: Current evidence supports the ability of Modified GRF 1-29 to stimulate endogenous growth hormone release through GHRH receptor activation. However, many commonly repeated claims regarding muscle gain, recovery enhancement, fat loss, and peptide-stacking superiority remain supported primarily by anecdotal experience rather than controlled human trials.
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Endocrinology literature
- Peer-reviewed growth hormone and metabolism journals
14. Last Reviewed
June 2026
1. Quick Facts
Category: Growth Hormone Secretagogue Stack
Risk Level: Moderate/High
Research Status: Emerging Research
Administration: Subcutaneous Injection
Typical Frequency: Nightly (No DAC) or Weekly/Twice Weekly (DAC)
Estimated Half-Life: Variable Depending on DAC vs No DAC Formulation
Primary Research Interest: HGH Support / Recovery / Body Composition / Sleep Support
This material is provided strictly for educational and informational purposes related to peptide research and endocrine compounds. CJC-1295 / Ipamorelin is a biologically active peptide stack capable of significantly altering growth hormone and IGF-1 signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
CJC-1295 / Ipamorelin is a peptide stack designed to stimulate endogenous growth hormone release through two complementary signaling pathways. CJC-1295 acts through Growth Hormone Releasing Hormone (GHRH) receptors, while Ipamorelin acts through ghrelin receptor pathways.
The combination has become one of the most widely discussed growth hormone secretagogue stacks within peptide communities due to its potential to support recovery, sleep quality, body composition, and growth hormone signaling without the use of exogenous HGH.
What People Commonly Claim
- Creates synergistic HGH release
- Provides many benefits of HGH without using HGH itself
- Improves sleep quality
- Accelerates recovery
- Promotes fat loss
- Supports lean muscle gain
- Produces a more natural growth hormone profile
What the Literature Actually Shows
- GHRH analogs and growth hormone secretagogues stimulate growth hormone release through complementary receptor systems.
- The biological rationale for combining the compounds is strong.
- Human studies directly evaluating the CJC-1295 / Ipamorelin combination remain limited.
- Many commonly cited benefits are inferred from growth hormone physiology and individual compound research rather than controlled trials of the stack itself.
- Long-term outcome data remain limited.
CKF Note: The pharmacology of this stack depends heavily on whether the CJC-1295 component contains DAC. CJC-1295 DAC and CJC-1295 No DAC (Modified GRF 1-29) have substantially different half-lives, administration schedules, and endocrine effects. Readers should verify which version is present in any blend or protocol being discussed.
3. Reconstitution Guide
- Blend Composition: CJC-1295 5 mg / Ipamorelin 5 mg
- Blend Ratio: 1 : 1
- Total Vial Size: 10 mg total blend
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL total blend concentration
At this concentration:
• 500 mcg = 0.100 mL (10 units)
4. Route of Administration
CJC-1295 / Ipamorelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue stack.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered before bedtime
- Administration Notes: Evening administration is frequently discussed because endogenous growth hormone release naturally increases during sleep.
5. Typical Research Protocols
- Product Strength: 5.00 mg/mL total blend concentration
- Typical Delivered Amount: 500 mcg every PM before bedtime
- Frequency: Daily (No DAC) or Weekly/Twice Weekly (DAC)
- Cycle Length: Commonly 12–24 weeks
- Special Notes: Whether the CJC-1295 component contains DAC or No DAC dramatically changes the pharmacokinetics of the stack. No DAC versions are commonly administered daily, while DAC-containing versions are often administered once or twice weekly due to the substantially extended half-life.
6. Mechanism of Action
The stack combines two distinct growth hormone secretagogue pathways:
- CJC-1295: Stimulates Growth Hormone Releasing Hormone receptors within the pituitary gland.
- Ipamorelin: Activates ghrelin receptors associated with growth hormone pulse signaling.
Together, the combination is intended to support:
- Increased endogenous growth hormone release
- Elevated IGF-1 signaling
- Recovery pathway activation
- Lipolysis support
- Sleep and recovery quality
Because the two compounds operate through different receptor systems, many researchers view the combination as mechanistically complementary.
7. Potential Benefits
- Potential fat-loss support
- Enhanced recovery from training stress
- Improved sleep quality
- Increased endogenous HGH signaling
- Potential connective tissue support
- Possible lean body composition improvements
8. Potential Risks / Side Effects
Moderate/High
- Water retention
- Numbness or tingling
- Elevated hunger
- Insulin sensitivity changes
- Headaches
- Potential endocrine dysregulation
- Elevated IGF-1 concerns
9. Half-Life
Half-life characteristics vary dramatically depending on whether the CJC-1295 component contains DAC.
CJC-1295 No DAC (Modified GRF 1-29) typically produces short-duration pulse-based activity, while DAC-containing versions may remain biologically active for several days.
Ipamorelin itself is relatively short acting, making protocol design highly dependent upon the specific CJC formulation utilized.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Diabetes or insulin resistance
- Severe endocrine disorders
- Known hypersensitivity to peptide compounds
12. Further Study
The CJC-1295 / Ipamorelin stack is one of the most commonly discussed peptide combinations for growth hormone support and recovery. However, much of the rationale for combining these compounds originates from complementary physiology and individual compound research rather than direct clinical trials evaluating the stack itself.
Recommended Reading
The Development of Growth Hormone-Releasing Hormone Agonists and Antagonists
A comprehensive review of GHRH analog development, physiology, and therapeutic applications.
Growth Hormone Secretagogues: Mechanism of Action and Clinical Utility
An overview of growth hormone secretagogue physiology and receptor biology relevant to compounds such as Ipamorelin.
CKF Transparency Note: Although CJC-1295 / Ipamorelin is one of the most widely discussed peptide stacks in recovery and body-composition communities, high-quality human studies directly evaluating the combination remain limited. Many reported benefits are extrapolated from growth hormone physiology and individual compound research rather than controlled studies of the stack itself.
Current Evidence Gaps
- Direct human trials evaluating CJC-1295 plus Ipamorelin
- Long-term outcome data
- Comparative trials versus HGH therapy
- Recovery outcomes in healthy adults
- Muscle gain outcomes in healthy adults
- Fat-loss outcomes in healthy adults
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Growth hormone physiology literature
- Peer-reviewed endocrinology journals
14. Last Reviewed
June 2026